Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Dong-Jin Jang | - |
dc.contributor.author | Jeong-Sook Park, | - |
dc.contributor.author | Hye-Ran Ko | - |
dc.contributor.author | Jun-Pil Jee | - |
dc.contributor.author | Jin-Ki Kim | - |
dc.contributor.author | Sung Tae Kim | - |
dc.contributor.author | Chong-Kook Kim | - |
dc.date.accessioned | 2021-06-23T23:41:26Z | - |
dc.date.available | 2021-06-23T23:41:26Z | - |
dc.date.created | 2021-01-21 | - |
dc.date.issued | 2005-01 | - |
dc.identifier.issn | 0269-3879 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/46153 | - |
dc.description.abstract | A high-performance liquid chromatographic (HPLC) method has been developed for the simultaneous determination of niflumic acid and its prodrug, talniflumate, in human plasma. Niflumic acid and talniflumate were eluted isocratically with methanol-water (73:27, v/v, adjusted to pH 3.5 by acetic acid) at a flow rate of I mL/min. Indomethacin was used as an internal standard. Signals were monitored by an UV detector at 288 nm. Retention times of indomethacin, niflumic acid and talniflumate were 5.9, 7.2 and 13.5 min, respectively. Calibration plots were linear over the range 50-5000 ng/mL for niflumic acid and 1005000 ng/mL for talniflumate. The limits of quantitation were 50 ng/mL for niflumic acid and 100 ng/mL for talniflumate. The intra- and inter-day relative standard deviations (RSD) of niflumic acid and talniflumate were less than 10% and the accuracies were higher than 90%. This method is rapid, sensitive and reproducible for the determination of niflumic acid and talniflumate in human plasma. Copyright (C) 2004 John Wiley Sons, Ltd. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | JOHN WILEY & SONS LTD | - |
dc.title | Simultaneous determination of niflumic acid and its prodrug, talniflumate in human plasma by high performance liquid chromatography | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jin-Ki Kim | - |
dc.identifier.doi | 10.1002/bmc.412 | - |
dc.identifier.scopusid | 2-s2.0-14544276357 | - |
dc.identifier.wosid | 000227233400006 | - |
dc.identifier.bibliographicCitation | BIOMEDICAL CHROMATOGRAPHY, v.19, no.1, pp.32 - 35 | - |
dc.relation.isPartOf | BIOMEDICAL CHROMATOGRAPHY | - |
dc.citation.title | BIOMEDICAL CHROMATOGRAPHY | - |
dc.citation.volume | 19 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 32 | - |
dc.citation.endPage | 35 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordAuthor | niflumic acid | - |
dc.subject.keywordAuthor | talniflumate | - |
dc.subject.keywordAuthor | prodrug | - |
dc.subject.keywordAuthor | high-performance liquid chromatography (HPLC) | - |
dc.identifier.url | https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/bmc.412 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.